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Abstract
Background: Chinchillas (Chinchilla laniger) are popular as pets and are often used as laboratory animals for
various studies. Pseudomonas aeruginosa is a major infectious agent that causes otitis media, pneumonia,
septicaemia enteritis, and sudden death in chinchillas. This bacterium is also a leading cause of nosocomial
infections in humans. To prevent propagation of P. aeruginosa infection among humans and animals, detailed
characteristics of the isolates, including antibiotic susceptibility and genetic features, are needed. In this study, we
surveyed P. aeruginosa distribution in chinchillas bred as pets or laboratory animals. We also characterized the
isolates from these chinchillas by testing for antibiotic susceptibility and by gene analysis.
Results: P. aeruginosa was isolated from 41.8% of the 67 chinchillas included in the study. Slide agglutination and
pulsed-field gel electrophoresis discriminated 5 serotypes and 7 unique patterns, respectively. For the antibiotic
susceptibility test, 40.9% of isolates were susceptible to gentamicin, 77.3% to ciprofloxacin, 77.3% to imipenem, and
72.7% to ceftazidime. DNA analyses confirmed that none of the isolates contained the gene encoding extended-
spectrum b-lactamases; however, 2 of the total 23 isolates were found to have a gene similar to the pilL gene that
has been identified in the pathogenicity island of a clinical isolate of P. aeruginosa.
Conclusions: P. aeruginosa is widely spread in chinchillas, including strains with reduced susceptibility to the
antibiotics and highly virulent strains. The periodic monitoring should be performed to help prevent the
propagation of this pathogen and reduce the risk of infection from chinchillas to humans.
Background
Chinchillas (Chinchilla laniger)a r ei nt h eR o d e n t i a
order, Hystricognathi suborder and the Chinchillidae
family. Since chinchillas are small and easy to breed,
they are popular as pets. Chinchillas have a large tympa-
num and cochlear duct similar to the human organ;
therefore, they are also often used as laboratory animals
for otolaryngological studies [1-4].
Pseudomonas aeruginosa is a Gram-negative rod-
shaped bacterium and an opportunistic pathogen that
causes various serious diseases in humans and animals.
Recently, this pathogen has acquired resistance to many
therapeutic antibiotics and, in particular, emergence of
P. aeruginosa isolates with extended-spectrum b-lacta-
mases (ESBLs) has become a serious problem in labora-
tories and hospitals [5-8]. Thus, it is important not only
to investigate the occurrence of P. aeruginosa infection
b u ta l s ot oa s s e s st h ee x i s t e n c e of antibiotic-resistant
P. aeruginosa strains to ensure the health of humans
and animals. It is known that chinchillas are sensitive to
P. aeruginosa infection and are therefore frequently used
as an animal model of diseases caused by P. aeruginosa,
including otitis media, otitis interna, pneumonia, septi-
caemia enteritis, and sudden death [9-12]. In early stu-
dies, various clinical treatments against P. aeruginosa
infection were discovered using chinchillas as an animal
model [11,13].
The clinical signs caused by natural infection of
P. aeruginosa in chinchillas bred as pets or laboratory
animals have been described. Doerning et al. [10]
reported that the occurrence of P. aeruginosa infection
in laboratory chinchilla colonies was thought to be
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water bottles. The clinical signs of P. aeruginosa infec-
tion have been shown to include otitis media and otitis
interna with neurologic manifestations, as well as fatal
symptoms in several animals [14]. Although experimen-
tal models of P. aeruginosa infection in chinchillas have
been well described in recent years, there are only few
reports on the distribution and abundance of natural
infection in chinchillas that are bred as laboratory ani-
mals or pets. Furthermore, in these case reports, mini-
mal epidemiological information was supplied.
Typing of P. aeruginosa strains and determining the
level of susceptibility to antibiotics are epidemiologically
useful for measuring the effectiveness of infection con-
trol in chinchillas. Minimum inhibitory concentrations
(MICs) are helpful indicators to select therapeutic sub-
stances and to detect the effects of previously used anti-
biotics. Zoonoses have long been considered one of the
most important threats in public health [15]. To prevent
propagation of P. aeruginosa infection among humans
and animals, detailed characteristics of the isolates,
including antibiotic susceptibility and genetic features,
may be needed. It is necessary to investigate this epide-
miological relationship not only for the health of labora-
tory animals and pets but also for human health.
In this study, we surveyed the occurrence of P. aerugi-
nosa infection among chinchillas bred as laboratory ani-
mals or pets. Subsequently, the epidemiological
characteristics of P. aeruginosa isolates, including sero-
type and molecular typing, were determined and we
tested for the presence of ESBLs in P. aeruginosa iso-
lates by DNA analysis.
Results
Surveillance of P. aeruginosa infection in chinchillas
A survey was carried out in 67 healthy chinchillas bred
both as pets and laboratory animals. Of these animals, 7
of 23 chinchillas bred as pets and 21 of 44 chinchillas
bred as laboratory animals were confirmed to be carriers
of P. aeruginosa. In all, 41.8% of otherwise-healthy
chinchillas were found to be carriers of P. aeruginosa.
The isolation of P. aeruginosa was carried out with swabs
from the oral cavity, faeces, and water bottles in the
chinchilla cage, with the detection rates of those swabs at
approximately 7%, 9%, and 20%, respectively. The detec-
tion rate of swabs from water bottles showed highly per-
centage among them. In 2 chinchillas, P. aeruginosa was
isolated with swabs from the oral cavity, faeces, and
water bottles, and in one chinchilla, P. aeruginosa was
isolated from both oral cavity and faeces.
Typing of P. aeruginosa isolates
Figure 1 shows the dendrogram and results obtained
from both serotype and pulsed-field gel electrophoresis
(PFGE) analysis. The serotype of all P. aeruginosa iso-
lates was determined using a slide agglutination test kit.
A total of 28 isolates were divided into 4 serotypes
(number of isolates): G type (9), B type (11), I type (1),
F type (2) and untypeable isolates (5). In the isolates
from chinchillas bred as pets, 2 G type and 5 untypeable
strains were identified; 11 and 7 B type and G type iso-
lates, respectively, were found in the isolates from
chinchillas bred as laboratory animals.
A total of 22 isolates were used to conduct the PFGE
analysis because 6 isolates could not be revived after
storage. The dendrogram was constructed from the
results of the band patterns of the PFGE analysis (Figure
1). Seven unique patterns were observed in P. aerugi-
nosa isolates from chinchillas (Additional file 1) and the
dendrogram corresponded to these serotypes. The iso-
lates were defined as identical PFGE types if they were
100% identical. Isolates from the same facility were clo-
sely related to each other, indicating that the typing of
the isolates by PFGE analysis and serotype contributed
to epidemiological data.
Antibiotic susceptibility
Figures 2A, B and 2C show the MICs for aminoglyco-
sides, fluoroquinolones, and selected b-lactams, respec-
tively. For the aminoglycoside susceptibility test, we
selected gentamicin and amikacin (Figures 2). Approxi-
mately 60% of the isolates exhibited an MIC value
greater than 8 μg/ml for gentamicin (Figure 2A).
According to MIC interpretive standards for P. aerugi-
nosa published by the National Committee Clinical and
Laboratory Standards (NCCLS) [16], 9 and 13 isolates
were susceptible and intermediate to gentamicin, respec-
tively. Only one isolate was intermediate to amikacin
according to the NCCL interpretive standards, and none
of the isolates showed resistance to these 2 aminoglyco-
sides (Figure 2B). With regard to fluoroquinolones, only
one isolate showed an MIC value of 4 μg/ml for cipro-
floxacin, while approximately 80% of the isolates showed
an MIC value greater than 4 μg/ml for enrofloxacin
(Figure 3A and 3B). According to the NCCL interpretive
standards, one isolate was resistant to ciprofloxacin.
Prior to sampling, 2 chinchillas bred as laboratory ani-
mals were treated with Baytril (enrofloxacin; Bayer,
Leverkusen, Germany) for 6 days and Gentacin (genta-
micin; Schering-plough animal health, Wim de Körver-
straat, Netherlands) for 2 days for otitis media. The
MICs of 2 isolates from these chinchillas were 2-4 μg/
ml for enrofloxacin and 4-8 μg/ml for gentamicin,
which may indicate that prior treatment led to the
reduced susceptibility to these antibiotics. Except for 2
chinchillas, none of animals was treated with antibiotics.
Further, we tested the b-lactam antibiotics that have
been mainly used for human treatment, including
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ins (Figure 4A, B, and 4C). Five isolates that exhibited
an MIC of 8 μg/ml were intermediate to imipenem,
while 16 isolates showed an MIC value less than 4 μg/
ml and were considered susceptible to imipenem
according to the NCCL interpretive standards. With
regard to cephalosporins, approximately 80% of the iso-
lates were confirmed to be susceptible to both ceftazi-
dime and cefepime; however, 6 and 1 isolates exhibited
an MIC value greater than 16 μg/ml for ceftazidime and
cefepime, respectively. For ceftazidime, these 6 isolates
were revealed to be intermediate according to the
NCCL interpretive standards. These results indicate that
the isolates from chinchillas had a reduced susceptibility
to the latter antibiotics used for humans, but not to
those used for animals.
Polymerase chain reaction (PCR) assay and sequencing
All isolates underwent PCR amplification to confirm the
existence of genes encoding various types of ESBLs in P.
aeruginosa wild strains [3,17]. None of the isolates were
found to contain ESBLs by using primer pairs for OXA,
TEM, SHV, PER, CTX group 2, CTX group 9 and VEB-
type ESBLs. By using primer pairs GES and CTX group1,
however, visible bands near the location of expected size
were observed in 9 and 2 isolates, respectively (data not
shown). To examine sequencing accuracy, TA cloning
was performed. By using the GES primer pair, all the
inserts that were sequenced were partially identified by
blastx search as the ATP-binding cassette (ABC) trans-
porter permease found in various strains of P. aeruginosa,
while none of the inserts were found to contain the gene
encoding the GES-type b-lactamase. By using the CTX
group 1 primer-pair, none of the inserts were found by
blastx search to contain the gene encoding the CTX-type
b-lactamase. However, all the inserts from 2 PCR ampli-
cons were highly similar to the gene encoding the puta-
tive PilL protein found in P. aeruginosa (accession no.
ABR13432), with 82% coverage and 97% maximum iden-
tity by blastx search. Further, all the inserts were also
similar to the gene encoding the type IV B pilus protein
in P. aeruginosa (accession no. YP_792920), with 81%
coverage and 95% maximum identity. Both the PilL and
type IV pilus protein were identified in a novel patho-
genicity island (PI) in highly virulent clinical isolates,
including strain PSE9 and PA14 [18-20]. Although the
Figure 1 Dendrogram of a total of 22 strains identified as Pseudomonas aeruginosa isolated from chinchillas by the unweighted-pair
group method with arithmetic averages based on pulsed-field gel electrophoresis analysis. The letters in parenthesis indicate the
serotype determined by the slide agglutination test kit (Denka Seiken, Tokyo, Japan) as follows: B, serotype B; F, serotype F; G, serotype G; I,
serotype I; NT, nontypeable strain.
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sequence but not the targeting gene, the 2 isolates were
confirmed to harbour the gene pilL.A l t h o u g hw e
attempted to isolate plasmid from these 2 strains, none
of them was confirmed to harbour plasmid. These results
also indicate that the 2 isolates containing the gene simi-
lar to pilL possibly also possess a PI in their genomes.
The two chinchillas that were infected with the P. aerugi-
nosa isolates containing the gene similar to pilL were
bred as laboratory animals and 2 isolates were found to
be susceptible to all tested antibiotics.
Although we also conducted tests to confirm the pro-
duction of metallo-b-lactamase (MBL) in all isolates, no
isolates were found to produce MBL. Compared with
the serotype and the PFGE type, there was no correla-
tion between typing and the susceptibility to antibiotics.
Although the genes coding for ESBLs were not detected
in chinchilla isolates using PCR assay and sequencing,
the 2 isolates containing the gene pilL may be highly
virulent strains of P. aeruginosa.
Discussion
In this study, all the chinchillas used for P. aeruginosa
isolation showed no clinical signs of P. aeruginosa infec-
tion or other bacterial infections, with the exception of 2
laboratory chinchillas with otitis media. P. aeruginosa
was isolated from 30.4% of pet chinchillas and 47.7% of
laboratory chinchillas. In total, P. aeruginosa was isolated
Figure 2 Minimum inhibitory concentrations (MICs) of aminoglycosides in 22 strains of Pseudomonas aeruginosa isolated from
chinchillas. (A) Gentamicin (B) Amikacin.
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Although otitis media caused by P. aeruginosa and their
clinical signs have been reported in many previous stu-
dies in chinchillas [9-12], there may be a latent period
explaining the lack of such symptoms in the infected ani-
mals included in our study. Further, clinical signs of P.
aeruginosa infection may be developed under immuno-
suppressive conditions in host animals. Many cases of P.
aeruginosa infection in chinchillas have been considered
to be caused by environmental contaminations such as
feed, water and flooring materials. In addition to these
contaminations, transient infections may result in silent
chronic infections in chinchillas due to coprophagia [21].
Although no evidence was found that the isolates from
chinchillas were heterogeneous, serotype and PFGE
analyses discriminated the isolates into 5 serotypes and
7 PFGE types, respectively. These results suggest that
the isolates diversified despite limited numbers. We
used slide agglutination for the determination of sero-
type as a minor modification of Homma’s method [22].
In early epidemiological studies, P. aeruginosa isolates
from both human and laboratory rodents were report-
edly predominantly serotype G, as determined by slide
agglutination [23,24]. Although serotype G was the sec-
ond most dominant serotype among the isolates in our
study, the isolates belonging to serotype G were further
discriminated into 3 independent PFGE types. Serotype
and PFGE type reportedly cross-react with each other
using slide agglutination; however, serotype G deter-
mined by Homma’s method was also divided into 2-4
Figure 3 Minimum inhibitory concentrations (MICs) of fluoroquinolones in 22 strains of Pseudomonas aeruginosa isolated from
chinchillas. (A) Enrofloxacin (B) Ciprofloxacin.
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(A) Imipenem (B) Ceftazidime (C) Cefepime.
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there may be no homogeneity in the degree of DNA
restriction analysis among these serotypes.
In this study, we determined MICs for 3 different
spectrums of antibiotics, including aminoglycosides,
fluoroquinolones, and b-lactams. Prior to the surveil-
lance, all the chinchillas bred as both pets and labora-
tory animals were confirmed to be receiving no
antibiotics, with the exception of 2 laboratory chinchil-
las. These 2 laboratory chinchillas were treated with
enrofloxacin and gentamicin. Although 2 isolates from
these animals were considered to be susceptible to enro-
floxacin, one of the isolates showed intermediate to gen-
tamicin. These results suggested that the treatment of
the antibiotics was led to the reduced susceptibility of
the isolate. In laboratory rodents, gentamicin and enro-
floxacin have been generally used for the treatment of
infectious diseases presumably caused by P. aeruginosa
or another Gram-negative bacterium [10,25,26], while
fluoroquinolones, carbapenems, and cephalosporins,
such as ciprofloxacin, imipenem, and cefepime, may not
be used for any bacterial infection in laboratory rodents
in Japan and are strictly reserved for human use. In our
study, no anamneses were found and none of antibiotics
were administered in pet chinchillas. Thus, the isolates
with reduced susceptibilities to ciprofloxacin, imipenem,
and cephalosporins were considered to be transmitted
by humans and the environment.
Recently, outbreaks of P. aeruginosa infections resistant
to various antibiotics have reportedly increased. Of these
infections, multidrug-resistant P. aeruginosa (MDRP),
including EBSL- and MBL-producing P. aeruginosa caus-
ing nosocomial infections, has become a serious problem
[27-30]. Therefore, the isolates from the chinchillas
included in our study were further used for the determi-
nation of susceptibility to the antibiotics to which MDRP
is resistant. From the antibiotic susceptibility tests, we
determined that no isolates exhibited high MIC values
for aminoglycosides, fluoroquinolones, or b-lactams. In
particular, none of the isolates showed an MIC value
greater than 16 μg/ml for imipenem and none revealed
positive results on MBL tests, indicating that the isolates
were not MDRP or MBL-producing P. aeruginosa.H o w -
ever, one isolate exhibited an MIC value greater than 32
μg/ml for ceftazidime, suggesting that this isolate may
have been an ESBL-producing P. aeruginosa strain.
In this study, the gene encoding ESBLs could not be
identified in P. aeruginosa isolates using previously
reported primers (Additional file 2). However, the iso-
lates that showed high MICs values for third and fourth
generation cephalosporins were considered to have the
genetic background for low susceptibility to these anti-
biotics. These genetic elements should be clarified in
future studies. Although the gene encoding ESBLs could
not be detected in the isolates using the primer pair
CTX group 1, TA cloning identified one of the genes
involved in pillin biogenesis. The partially identified
gene was similar to the pilL gene that has been reported
to be located in the PI of a virulent strain of P. aerugi-
nosa [20]. The PI we observed was also homologous to
ap r e v i o u s l yi d e n t i f i e dP. aeruginosa PI (PAPI-1) that
was only found in strain PA14, which is highly virulent
for animals and plants [18,19]. The genes encoding PilL
and type IV B pilus protein were not identified in less
virulent strains of P. aeruginosa,s u c ha ss t r a i nP A O 1 ,
b u to n l yi nh i g h l yv i r u l e n tc linical isolates, including
strain PSE9 and PA14. Both proteins were previously
found to be related to type IV pillin in the newly discov-
ered PI [19,20]. Type IV pillin has been shown to be one
of the most important factors for adherence to and inva-
sion of host cells during infection [31]. For P. aerugi-
nosa, the existence of the PI, such as PAPI-1, is
considered to be closely related to virulence and patho-
genicity for host animals. Thus, monitoring P. aerugi-
nosa using genetic information, including the existence
of a PI and antibiotic resistance, may help prevent the
propagation of the pathogen.
Conclusions
In this study, P. aeruginosa was isolated at high rates from
pet and laboratory chinchillas. Typing analysis showed
that the isolates were diversified, and the antibiotic sus-
ceptibility test showed low susceptibility levels in several
isolates. Although we could not identify the gene encoding
ESBLs, the isolates were found to contain the gene pilL
t h a tw a sp r e v i o u s l yi d e n t i f i e do n l yi nh i g h l yv i r u l e n t
strains of P. aeruginosa. Thus, it is necessary to take into
account the risk of infection from pets or laboratory
chinchillas to humans. Because of rapid disease progres-
sion and high mortality rates often seen in chinchillas [10],
maintaining a clean environment and monitoring should
be performed to help prevent P. aeruginosa infection.
Methods
Isolation and identification of P. aeruginosa from
chinchillas
The isolation of P. aeruginosa was carried in a total of
67 chinchillas, including 23 pets and 44 from 2 breeding
facilities for use as laboratory animals. Chinchillas that
were used for the isolation of P. aeruginosa were all
healthy and had no clinical signs, but 1 chinchilla with
otitis media was excluded. Further, 2 chinchillas bred as
laboratory animals were treated with Baytril for 6 days
and Gentacin for 2 days due to otitis media. These 2
laboratory chinchillas recovered completely from otitis
media prior to sampling. Oral cavity, faeces, and indivi-
dual water bottle swabs were collected from each
chinchilla and diluted with sterilized saline. The samples
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Tokyo, Japan) and incubated at 37°C for 48 h. Isolates
were identified on the basis of colony pigment, Gram
staining, and catalase activity. Subsequently, the isolates
were identified as P. aeruginosa using Quick ID GN"Nis-
sui” (Nissui). The serotype of P. aeruginosa isolates was
determined with a slide agglutination test kit (Denka
Seiken, Tokyo, Japan). Isolates that did not react to any
antisera were determined to belong to a nontypeable
strain. The glycerol stock of isolates was kept at -80°C
until analysis. After this time, 6 isolates could not be
revived, and therefore, a total of 22 isolates were used
for the analyses. To ensure the accuracy of the identifi-
cation procedures, 2 reference strains of P. aeruginosa
ATCC 27853 (American Type Culture Collection, Man-
assas, VA, USA) and IID 1130 (The Institute of Medical
Science, The University of Tokyo, Tokyo, Japan) were
used in comparative analyses. Chinchillas were treated
in accordance with the provisions for animal welfare of
The Nippon Veterinary and Life Science University (for-
merly The Nippon Veterinary and Animal Science Uni-
versity), which follows the Guidelines for Animal
Experimentation issued by the Japanese Association for
Laboratory Animal Science.
Pulsed-field gel electrophoresis analysis
PFGE was carried out as described previously [32,33].
Briefly, all isolates, which were grown in nutrient broth
overnight at 37°C, were centrifuged at 10,000 g for 2 min.
The pellet was resuspended and mixed with 1% agarose.
Lysis was performed at 37°C for 1 h, followed by protei-
nase K digestion at 50°C for 16 h. After 4 washing steps,
all plugs were digested with SpeI for 16 h at 25°C. After
SpeI digestion, the fragments were separated by electro-
phoresis in 1% agarose gels with a CHEF-DR apparatus
(Bio-Rad, CA, USA) for 18 h, with the switch times ran-
ging from 5.3 s to 34.9 s and a field strength of 6 V/cm
2.
Lambda ladders were applied as molecular size makers
(Bio-Rad). The gels were stained for 20 min with ethidium
bromide and destained for 20 min thereafter. After being
photographed under UV, fragment patterns were com-
pared visually and cluster analysis by the unweighted-pair
group method with arithmetic averages was performed
using NTSYSpc (Exeter Software, NY, USA), as described
previously [34].
Antibiotic susceptibility test
MICs were defined as the lowest concentration of anti-
biotics that showed no visible growth after 24 h of incu-
bation at 35°C. The MICs of antibiotics for all isolates
were measured using a broth microdilution technique
described by the Clinical and Laboratory Standards
Institute [16]. Antimicrobials were obtained from the
following sources: gentamicin (ICN Biomedicals, Aurora,
Ohio), amikacin (Bristol Laboratories, Belleville, Ontario,
Canada), imipenem (Merck, NJ, USA), ceftazidime (LKT
Laboratories, MN, USA), cefepime (Bristol-Myers
S q u i b b ,N Y ,U S A ) ,e n r o f l o x a cin (MP Biomedicals, OH,
USA), and ciprofloxacin (LKT Laboratories). All antimi-
crobials were thawed and diluted to the desired concen-
trations with cation-adjusted Mueller-Hinton II broth
(BD, MD, USA) prior to each susceptibility test. Each
test was repeated at least 3 times. All isolates were
assessed for the production of MBLs using metallo-b-
lactamase SMA “Eiken” (Eiken, Tokyo, Japan). To verify
the susceptibility of isolates, the MIC values of amino-
glycosides, ciprofloxacin, imipenem, and ceftazidime
were compared with the description of the NCCL inter-
pretive standards [16].
DNA manipulation
We used PCR techniques to detect the gene encoding
various types of ESBLs found in P. aeruginosa using the
methods of Jiang et al. [17] and Weldhagen [8]. In brief,
PCR was used to detect the gene encoding b-lactamases,
OXA-10, TEM, SHV, PER-1, CTX group 1, CTX group
2, CTX group 9, VEB-1and GES (Additional file 2). The
amplicons were confirmed by agarose gel electrophor-
esis, and visualized bands were subsequently purified
with Suprec PCR (Takara bio, Shiga, Japan). The puri-
fied PCR products were ligated with T-vector, pTAC-1
using a TA PCR cloning kit (Biodynamics laboratory,
Tokyo, Japan), and the resulting plasmids transformed
in Escherichia coli DH5a were spread on Luria-Bertani
medium supplemented with 100 μg/ml ampicillin. The
colonies were randomly picked up and screened directly
for inserts by performing colony PCR with primers
M13-f and M13-r (Additional file 2). The PCR products
were purified and cycle sequencing reaction was con-
ducted using the BigDye terminator cycle sequencing kit
(Applied Biosystems). The products were then analyzed
using an ABI 310 DNA sequencer (Applied Biosystems).
The closest matches of the sequences were identified by
blastx search. For the several isolates, existence of plas-
mid was confirmed to isolate plasmid DNA using a
Miniprep DNA purification kit (Takara). The results
were confirmed on agarose gels under UV.
Nucleic acid accession numbers
The nucleotide sequences of partial genes encoding
ABC transporter permease (G-1) and PilL protein (C-1)
were deposited in GenBank through DNA Data Bank of
Japan (DDBJ), and the accession numbers assigned were
AB591379 and AB591380, respectively.
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Additional file 1: Pulsed-field gel electrophoresis binding patterns
of selected reference strains and wild-type strains of Pseudomonas
aeruginosa after SpeI digestion of total DNA. Lanes: M, Bacteriophage
lambda ladder DNA; 1, MA8; 2, MA6; 3, N3; 4, N2; 5, N4; 6, A1; 7, IID 1130;
8, MA4; 9, ATCC 27853.
Additional file 2: Primers used for polymerase chain reaction and
sequencing. Nucleotide sequences of primers used for PCR, TA cloning
and sequencing were described. ESBL = extended-spectrum b-lactamase.
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